期刊文献+

肥厚型心肌病QT离散度的临床意义及倍他乐克的作用 被引量:2

下载PDF
导出
摘要 目的:探讨肥厚型心肌病QT离散度的临床意义及倍他乐克对其的作用。方法:根据超声结果将患者分梗阻组和非梗阻组,为每个患者记录体表常规12导联同步心电图,分别计算QT、QT离散度(QTd)、校正的QT离散度(QTcd)。在治疗过程中给予倍他乐克,以12.5mg,2次/d起始,逐渐加量至目标剂量。在给药前、给药后1个月和3个月复查。结果:梗阻性肥厚型心肌病和非梗阻性肥厚型心肌病QT,QTd,QTcd均超过正常值(P<0.01);倍他乐克能明显缩短两组的QTd,且梗阻组QTd的变化程度较非梗阻组更显著(P< 0.05)。结论:两组肥厚型心肌病QT,QTd,QTcd均超过正常值,倍他乐克能明显缩短两组的QTd,且梗阻组QTd的变化程度较非梗阻组更显著,有利于改善患者预后。
出处 《实用诊断与治疗杂志》 2007年第4期308-309,共2页 Journal of Practical Diagnosis and Therapy
  • 相关文献

参考文献7

二级参考文献43

  • 1赵颖,齐峰.老年充血性心力衰竭β受体阻滞剂的应用[J].中国误诊学杂志,2004,4(8):1236-1238. 被引量:3
  • 2姜坚.赖诺普利与氯沙坦治疗心力衰竭对心室重构的影响[J].实用诊断与治疗杂志,2005,19(12):876-878. 被引量:7
  • 3[1]Braunwald E.Unstable angina,a classification.Circulation,1989,80:410
  • 4[2]Doven O,Ozdol C,Sayin TM,et al.QT interval dispersion:non-invasive marker of ischemic injury in patients with unstable angina pectoris? Jpn Heart J,2000,41(5):597
  • 5Anderson J L, Prystowsky E N. Sotalol: an important new antiarrhythmic[J]. Am Heart J, 137 : 388.
  • 6The Antiarrhythmics Verus Implantable Defibrillation (AVID)Investigators. A comparison of Antiarrhythmic-durg therapy with implantable defibrillators in patients resuscitated from nearfatal ventricular arrhythmias[J]. N Engl J Med,1997,337:157.
  • 7Moss A J. Implantable cardioverter defibrillator therapy. The sickest patients benefit the most[J]. Circulation,2000,101:1638.
  • 8Packer M. Therapeutic options in the management of chronic heart failure[J]. Circulation, 1989,79 : 198.
  • 9CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure:the Cardiac Insufficiency Bisoprolol Study (CIBIS) [J]. Circulation, 1996,94 : 2800.
  • 10E M, Kaye D, Lambert G,et al. Adrenergic nervous system in heart failure[J]. Am J Cardio, 1997,80: 7.

共引文献65

同被引文献13

  • 1陆洁,张大东,肖红兵,金贤.靶剂量开搏通、倍他乐克在扩张型心肌病合并充血性心力衰竭治疗中的疗效评价[J].实用诊断与治疗杂志,2007,21(1):17-19. 被引量:9
  • 2颜彦,王翔飞,王蚰南,王健生,施月芳,潘文明,黄国倩,聂振宁,葛均波.扩张性低收缩性状态——肥厚型心肌病的特殊演变[J].复旦学报(医学版),2007,34(2):198-201. 被引量:5
  • 3Yoshida M, Nakamura Y, Fukuhara T, et al. Prognostic determinants of hypertrophic cardiomyopathy--the results of the Shiga Cardiomyopathy Study[J]. Jpn Circ J,1995.59(11):745-753.
  • 4Kawashima T, Yokota Y, Yokoyama M, et al. Pathy simulating dilated cardiomyopathy[J]. Acta Pathol Jpn, 1993,43(3):304-312.
  • 5Cecchi F. Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy[J]. N Engl J Med,2003,349(11): 1027-1035.
  • 6Terai H. Shimizu M, Ino H, et al. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy [J]. J Nucl Med,2003,44(10):1612-1619.
  • 7Kamisago M. Sharma S D. DePalma S R, et al. Mutations in sareomere protein genes as a cause of dilated cardiomyopathy[J]. N Engl J Med.2000,343(23) :1688-1696.
  • 8Biagini E. Coccolo F, Ferlito M, et al. Dilated hypokinetlc evolution of hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2005.46(8) :1543-1550.
  • 9林传骧.肥厚型梗阻原发性心肌病.中华内科杂志,1984,:387-387.
  • 10Biagini E,Coccolo F,Ferlito M,et al.Dilated-hypokinetic evolution of hypertrophic cardiomyopathy[J].J Am Coll Cardiol,2005,46(8):1543-1550.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部